Breadcrumb Navigation

Melanom: A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

Stadium/Indikation inkl. Kurzinfo

Melanom – 2nd line

Stadium III oder IV
BRAF oder NRAS mutiert

panRAF Inhibitor + ERK Inhibitor oder MEK Inhibitor oder CDK4 and CDK6 Inhibitor

Kurztitel

Novartis CLXH254C12201
NCT04417621

Offizieller Titel

A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

PI

Prof. Reinhard Dummer

Zuständige Ärztin

Corinne Eggenschwiler

Tel. +41 43 253 03 96

Behandelnder Fachbereich

Dermatologische Klinik